These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24764226)

  • 1. Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer.
    Rodríguez M; Silva J; López-Alfonso A; López-Muñiz MB; Peña C; Domínguez G; García JM; López-Gónzalez A; Méndez M; Provencio M; García V; Bonilla F
    Genes Chromosomes Cancer; 2014 Sep; 53(9):713-24. PubMed ID: 24764226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of microRNAs derived from exosomes in bronchoalveolar lavage fluid of early-stage lung adenocarcinoma: A pilot study.
    Kim JE; Eom JS; Kim WY; Jo EJ; Mok J; Lee K; Kim KU; Park HK; Lee MK; Kim MH
    Thorac Cancer; 2018 Aug; 9(8):911-915. PubMed ID: 29806739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF-alpha, IL-1 and IL-6 concentration in bronchoalveolar lavage fluid (BALF) of non-small cell lung cancer (NSCLC).
    Chyczewska E; Mróz RM; Kowal E
    Rocz Akad Med Bialymst; 1997; 42 Suppl 1():123-35. PubMed ID: 9337531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomal microRNA: a diagnostic marker for lung cancer.
    Rabinowits G; Gerçel-Taylor C; Day JM; Taylor DD; Kloecker GH
    Clin Lung Cancer; 2009 Jan; 10(1):42-6. PubMed ID: 19289371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of insulin like growth factor 1 and insulin like growth factor binding protein 3 levels in bronchoalveolar lavage fluid and serum of patients with lung cancer.
    Unsal E; Köksal D; Yurdakul AS; Atikcan S; Cinaz P
    Respir Med; 2005 May; 99(5):559-65. PubMed ID: 15823452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High neuron specific enolase levels in bronchoalveolar lavage fluid of patients with lung carcinoma: diagnostic value, relation to serum neuron specific enolase, and staging.
    Dowlati A; Bury T; Corhay JL; Weber T; Mendes P; Radermecker M
    Cancer; 1996 May; 77(10):2039-43. PubMed ID: 8640667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasminogen activator inhibitor type 1 (PAI-1) in blood and tissue extracts of patients with non-small cell lung cancer].
    Zekanowska E; Cieśliński K; Rość D
    Pneumonol Alergol Pol; 2004; 72(9-10):409-14. PubMed ID: 16021996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temperature and serum proinflammatory cytokine changes in patients with NSCLC after BAL.
    Georgiades G; Myrianthefs P; Venetsanou K; Kythreoti A; Kyroudi A; Kittas C; Baltopoulos G
    Lung; 2003; 181(1):35-47. PubMed ID: 12879338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble Human Leukocyte Antigen-G in the Bronchoalveolar Lavage of Lung Cancer Patients.
    Montilla D; Pérez M; Borges L; Bianchi G; Cova JA
    Arch Bronconeumol; 2016 Aug; 52(8):420-4. PubMed ID: 27004472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosome-derived miRNAs and ovarian carcinoma progression.
    Vaksman O; Tropé C; Davidson B; Reich R
    Carcinogenesis; 2014 Sep; 35(9):2113-20. PubMed ID: 24925027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of serum proteome components associated with progression of non-small cell lung cancer.
    Pietrowska M; Jelonek K; Michalak M; Roś M; Rodziewicz P; Chmielewska K; Polański K; Polańska J; Gdowicz-Kłosok A; Giglok M; Suwiński R; Tarnawski R; Dziadziuszko R; Rzyman W; Widłak P
    Acta Biochim Pol; 2014; 61(2):325-31. PubMed ID: 24872961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-2 concentration in bronchoalveolar lavage fluid (BALF) of non-small cell lung cancer (NSCLC) patients.
    Chyczewska E; Mróz RM; Kowal E
    Rocz Akad Med Bialymst; 1997; 42 Suppl 1():136-45. PubMed ID: 9337532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
    Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
    Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of the opioid peptide Leu-Val-Val-hemorphin-7 from bronchoalveolar lavage fluid of a patient with non-small cell lung cancer.
    Duethman D; Dewan N; Conlon JM
    Peptides; 2000 Jan; 21(1):137-42. PubMed ID: 10704729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer.
    Gao J; Qiu X; Li X; Fan H; Zhang F; Lv T; Song Y
    Biochem Biophys Res Commun; 2018 Apr; 498(3):409-415. PubMed ID: 29452091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer.
    Ferretti G; Curigliano G; Pastorino U; Cittadini A; Flamini G; Calabrò MG; De Pas T; Orlando L; Mandalà M; Colleoni M; Spaggiari L; Granone PL; Pagliari G; de Braud F; Fazio N; Goldhirsch A
    Clin Cancer Res; 2000 Jun; 6(6):2393-400. PubMed ID: 10873091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer.
    Yuan A; Yang PC; Yu CJ; Chen WJ; Lin FY; Kuo SH; Luh KT
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1957-63. PubMed ID: 11069840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No Significant Difference between Plasma miRNAs and Plasma-Derived Exosomal miRNAs from Healthy People.
    Tian F; Shen Y; Chen Z; Li R; Ge Q
    Biomed Res Int; 2017; 2017():1304816. PubMed ID: 28656135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoproteomic analysis of bronchoalveolar lavage (BAL) fluid identifies tumor-associated glycoproteins from lung adenocarcinoma.
    Li QK; Shah P; Li Y; Aiyetan PO; Chen J; Yung R; Molena D; Gabrielson E; Askin F; Chan DW; Zhang H
    J Proteome Res; 2013 Aug; 12(8):3689-96. PubMed ID: 23802180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.